Business Wire

Nitto Extends Partnership with the ATP Until 2030

Share

Nitto Denko Corporation (Headquarters: Osaka, Japan; President: Hideo Takasaki; hereafter “Nitto”)(TOKYO:6988) is pleased to announce the extension of its partnership with the ATP for an additional five years, through 2030. Under this renewed agreement, Nitto will continue its role as the Title Partner of the Nitto ATP Finals, the season-ending championship, in collaboration with the ATP and the Italian Tennis and Padel Federation (FITP). By sponsoring this tournament, recognized as one of the most sustainable events on the ATP Tour, Nitto aims to inspire and amaze while pursuing further growth as a global company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116197903/en/

Nitto Extends Partnership with the ATP Until 2030 : ©Corinne Dubreuil/ATP Tour

Since 2017, Nitto has served as the Title Partner of the Nitto ATP Finals―the year-end climax of the men's professional tennis circuit featuring the world’s the top eight singles players and eight doubles teams. The tournament will continue to be held in Italy through 2030.

Nitto's business strategy, which aims for world leadership across diverse fields, shares common ground with the men's professional tennis season finale, where the world’s best players rise to the challenge of competing for the ATP Tour’s most prestigious title.

Through the partnership with this tournament, Nitto will achieve greater leaps as a global enterprise and create innovation alongside customers. By creating essential value, Nitto will continue to grow globally.

Hideo Takasaki, Nitto President, CEO said:
“We are pleased to announce to our stakeholders the continuation of our title sponsorship of the Nitto ATP Finals. Since the inception of our partnership in 2017, we have consistently supported players striving for excellence, recognizing parallels with our own Global Niche Top™ strategy. Furthermore, the players' bold pursuit of challenges has fostered a culture of taking on challenges within the Nitto Group, transcending organizational boundaries, and has served as a profound source of inspiration. We remain committed to drive to further growth and hope this tournament continues to deliver amazement and inspiration to fans around the world."

Eno Polo, ATP CEO, said:
“Nitto has been our trusted partner for almost a decade now. Their commitment to the Nitto ATP Finals has helped make it what it is today – a world-class experience for both fans and players. Their impact doesn’t stop there – they’ve fully embraced sustainability, leading the way in building an event that drives real, positive change. We’re proud to keep working with a partner equally invested in pushing our sport to new heights.”

About The ATP

As a global governing body of men’s professional tennis, the ATP’s mission is to serve tennis. ATP entertains a billion global fans, showcases the world’s greatest players at the most prestigious tournaments, and inspires the next generation of fans and players. From the United Cup in Australia, to Europe, the Americas and Asia, the stars of the game battle for titles and PIF ATP Rankings points at ATP Masters 1000, 500 and 250 events, and Grand Slams. All roads lead towards the Nitto ATP Finals, the prestigious season finale held in Turin, Italy.
Featuring only the world’s top 8 qualified singles players and doubles teams, the tournament also sees the official crowning of the year-end ATP World No. 1, presented by PIF, the ultimate achievement in tennis. For more information, please visit www.ATPTour.com.

About Nitto (Nitto Denko Corporation) 

Nitto is a high-performance materials manufacturer that leverages eight core technologies-developed since its founding in 1918-to deliver a diverse range of products and services worldwide. These include optical materials such as polarizing film for display devices, circuit boards, industrial tapes, and medical-related products. Guided by its brand slogan “Innovation for Customers,” Nitto strives to create essential value for society while contributing to a sustainable global environment and an enriched human society.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251116197903/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r

Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset

Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release

Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release

Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline17.11.2025 07:00:00 CET | Press release

At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters™*1-3 Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 The company also presented new phase III data on its investigational product Relfydess™ (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Inje

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye